Microscopic biliary and perineural invasion and clinical outcome after neoadjuvant bevacizumab-based chemotherapy and liver resection in patients with colorectal liver metastases
- 1 January 2018
- journal article
- research article
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 44 (1) , 139-147
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Neoadjuvant chemotherapy (NCT) plus targeted agents versus NCT alone in colorectal liver metastases patients: A systematic review and meta-analysisOncotarget, 2015
- Critical review of the prognostic significance of pathological variables in patients undergoing resection for colorectal liver metastasesHPB, 2014
- Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trialThe Lancet Oncology, 2013
- Liver Resection for Colorectal Metastases after ChemotherapyAnnals of Surgery, 2013
- Bevacizumab Improves Pathological Response of Colorectal Cancer Liver Metastases Treated with XELOX/FOLFOXAnnals of Surgical Oncology, 2010
- Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved ChemotherapyJournal of Clinical Oncology, 2009
- Bevacizumab, Capecitabine, and Oxaliplatin As Neoadjuvant Therapy for Patients With Potentially Curable Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Clinical Score for Predicting Recurrence After Hepatic Resection for Metastatic Colorectal CancerAnnals of Surgery, 1999
- Factors influencing survival of patients undergoing hepatectomy for colorectal metastasesBritish Journal of Surgery, 1999